High Flow Cannula Therapy In Bronchiolitis, A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,283,342.00
Summary
Bronchiolitis is the leading cause of paediatric hospitalisation in Australia. Despite multiple research studies the outcome has not changed. Our recent studies supported by other international studies have shown that the use of high flow nasal cannula oxygen may reduce the severity and prevent progression of the disease. We aim to investigate if HFNC in regional hospitals can reduce the number of infants transferred to specialist children’s hospitals and reduce the socio-economic burden.
The Emerging Problem Of Non-tuberculous Mycobacteria Infection: Understanding Aetiology, Geospatial Epidemiology And Developing Interventions
Funder
National Health and Medical Research Council
Funding Amount
$988,791.00
Summary
This project will be largest study of non-tuberculous mycobacterial (NTM) infection in cystic fibrosis. By combining growing the bacteria with detailed information from the CF patient data registry, geographical location and environmental conditions, this study will provide novel insights into factors associated with NTM. Gene sequencing and airway infection profiling will extend understanding and has the potential to identify novel risk factors and biomarkers for NTM-related airways disease.
Inhibition Of IFN-?/? By Human Metapneumovirus And The Induction Of Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$605,251.00
Summary
The newly isolated human metapneumovirus (hMPV) causes significant respiratory illness in infants, young children and the elderly. The virus can persist long-term and may predispose individuals to chronic lung disease. This proposal aims to determine the mechanisms by which hMPV infection causes respiratory disease, with a view to improving treatments and preventing disease.
Identification Of Proteins Specific To Transmissible Pseudomonas Aeruginosa In Cystic Fibrosis Infection
Funder
National Health and Medical Research Council
Funding Amount
$443,007.00
Summary
Cystic fibrosis (CF) is the most common autosomal recessive disorder in humans, affecting 1:2000 people. Mortality is often caused by Pseudomonas aeruginosa lung infections which have recently been shown to occur not only environmentally but also via person-person contact, usually during CF clinic visits. This project will elucidate the molecular traits responsible for these 'epidemic' P. aeruginosa infections, with the aim of finding novel therapeutics and infection control strategies.
Circulatory Biomarkers For Idiopathic Pulmonary Fibrosis: Improving Patient Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$841,625.00
Summary
We are going to find molecules in the blood that would improve the diagnosis and treatment of a lung condition called Idiopathic Pulmonary Fibrosis (IPF). The project brings together well characterized patients from the Australian IPF registry, blood samples we have collected from them and cutting edge technologies to complete this project.
The Link Between Vitamin D Deficiency And Chronic Lung Disease Is Due To Increased Airway Smooth Muscle
Funder
National Health and Medical Research Council
Funding Amount
$644,067.00
Summary
Vitamin D deficiency is a global public health problem. It is becoming increasingly evident that vitamin D deficiency increases the severity of chronic lung disease. In this study we propose to examine a mechanism that we think clearly explains this association. These studies are critical to understanding how deficiencies in key nutrients can impact on chronic lung disease and will provide the data necessary to guide public health policy to reduce the burden of disease in the community.
Role Of Viruses In The Development Of Lung Disease In Cystic Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$1,223,186.00
Summary
This study will investigate how lung disease starts in babies with cystic fibrosis and the role of viral infections in this process. The new knowledge gained will help us move towards treatments that prevent or delay the start of lung disease, something not currently possible. We believe this new treatment paradigm will lead to improved quality and extent of life of those with cystic fibrosis.
Molecular Dissection Of Aberrant IL6/gp130 And TGF? Signaling In The Pathogenesis Of Interstitial Pneumonitis
Funder
National Health and Medical Research Council
Funding Amount
$590,009.00
Summary
Interstitial pneumonia (IP) is frequently observed in the group of lung diseases which affect the transfer of oxygen from inhaled air into the bloodstream. Current treatments for these diseases only effectively manage patient’s symptoms but don’t cure patients of IP. We have developed a strategy to identify the exact cell type responsible for an acute IP and the molecular intermediates that may offer novel treatments and pave the way for a possible cure for this disease.
The Predictors Of Asthma And Lung Function Deficits In The Third Decade: Longitudinal Study Of MACS Sibships
Funder
National Health and Medical Research Council
Funding Amount
$1,176,908.00
Summary
This will be the world’s first birth cohort study to use substantial prospective data to investigate how biological, psychosocial, and environmental markers from birth will predict asthma and lung function in the third decade of life. Our findings will be crucial to the development of new policy and practice for the prevention and management of these conditions and uncover crucial risk factors for young adult asthma.
Role Of The LIM-only Protein LMO4 In Lung Development And Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$490,395.00
Summary
Lung cancer is the leading cause of death in cancer patients in Australia. Although treatments have improved in the past 10 years, new therapeutic strategies are eagerly awaited. Deregulation of molecules driving development of normal tissue is often observed in cancer. Our aim is to identify key regulators of lung development and lung repair after injury. We aim to evaluate the role of these molecules in the initiation and progression of lung cancer to identify new targets for therapies.